Carbonic Anhydrase-IX Guided Albumin Nanoparticles for Hypoxia-mediated Triple-Negative Breast Cancer Cell Killing and Imaging of Patient-derived Tumor

• Published in: Molecules (Basel, Switzerland) Switzerland), 2020-05, Vol.25 (10), p.2362
• Main Authors: Tatiparti, Katyayani, Rauf, Mohd Ahmar, Sau, Samaresh, Iyer, Arun K
• Format: Article
• Language: English
• Subjects: Acetazolamide; Albumins - chemistry; Animals; Antigens, Neoplasm - genetics; Apoptosis; Apoptosis - drug effects; Bioavailability; Bovine serum albumin; Breast cancer; Cancer therapies; Carbonic anhydrase; Carbonic Anhydrase IX - genetics; carbonic anhydrase-IX; Cell death; Cell Line, Tumor; Cell Proliferation - drug effects; Chemistry; Clinical trials; Curcumin; Curcumin - analogs & derivatives; Curcumin - chemistry; Curcumin - pharmacology; Cytotoxicity; Diarylheptanoids - chemistry; Diarylheptanoids - pharmacology; Drug delivery systems; Drugs; Dyes; Encapsulation; ErbB-2 protein; Estrogens; Fluorescence; Gene Expression Regulation, Neoplastic - drug effects; Humans; Hypoxia; Internalization; Kinases; Ligands; Liver; Metabolism; Mice; Nanoparticles; Nanoparticles - chemistry; Permeability; Pharmaceutical industry; Progesterone; Proteins; Serum albumin; Serum Albumin, Bovine - chemistry; Serum Albumin, Bovine - pharmacology; Spleen; Stroma; TNBC; Triple Negative Breast Neoplasms - drug therapy; Triple Negative Breast Neoplasms - genetics; Triple Negative Breast Neoplasms - pathology; tumor hypoxia; Tumor Hypoxia - drug effects; Tumors; Xenograft Model Antitumor Assays; Xenografts; Xenotransplantation
• ISSN: 1420-3049; 1420-3049
• DOI: 10.3390/molecules25102362

Triple-Negative Breast Cancer (TNBC) is considered as the most onerous cancer subtype, lacking the estrogen, progesterone, and HER2 receptors. Evaluating new markers is an unmet need for improving targeted therapy against TNBC. TNBC depends on several factors, including hypoxia development, which contributes to therapy resistance, immune evasion, and tumor stroma formation. In this study, we studied the curcumin analogue (3,4-Difluorobenzylidene Curcumin; CDF) encapsulated bovine serum albumin (BSA) nanoparticle for tumor targeting. For tumor targeting, we conjugated Acetazolamide (ATZ) with CDF and encapsulated it in the BSA to form a nanoparticle (namely BSA-CDF-ATZ). The in vitro cytotoxicity study suggested that BSA-CDF-ATZ is more efficient when compared to free CDF. The BSA-CDF-ATZ nanoparticles showed significantly higher cell killing in hypoxic conditions compared to normoxic conditions, suggesting better internalization of the nanoparticles into cancer cells under hypoxia. Fluorescent-dye labeled BSA-CDF-ATZ revealed higher cell uptake of the nanoparticle compared to free dye indicative of better delivery, substantiated by a high rate of apoptosis-mediated cell death compared to free CDF. The significantly higher tumor accumulation and low liver and spleen uptake in TNBC patient-derived tumor xenograft models confirm the significant potential of BSA-CDF-ATZ for targeted TNBC imaging and therapy.